Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Investor Presentation (November 2021)
21 slides from Century Therapeutics's investor presentation, Nov 18, 2021
Slide 1: Corporate Overview November 2021
CORPORATE OVERVIEW November 2021
Slide 2: Forward-Looking Statements
2 2 FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbour provisions of , The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical f
Slide 3: Century Therapeutics - Emerging Leader in iPSC Cell Therapies
3 3 CENTURY THERAPEUTICS - EMERGING LEADER IN i PSC CELL THERAPIES EMPLOYEES INCLUDING EXPERIENCED LEADERS AND ENTREPRENEURS ~150 COMPREHENSIVE iPSC CELL PLATFORM FOR IMMUNE EFFECTOR CELLS LEAD PROGRAM ON TRACK TO FILE IND MID 2022 STATE - OF - THE ART GMP MANUFACTURING FACILITY EXPECTED TO BE OPERA
Slide 4: We Are Building a Next Generation Cell Therapy Platform
4 4 WE ARE BUILDING A NEXT GENERATION CELL THERAPY PLATFORM Autologous (Patient derived) Allogeneic (Healthy donor derived) iPSC derived • C omplex genetic editing • High replication capacity • Streamlined manufacturing • C onsistent product • Lengthy, expensive manufacturing • Potential weakened do
Slide 5: Proven Leadership Team
5 5 Osvaldo (Lalo) Flores, CEO Hy Levitsky , President R&D Adrienne Farid, COO Greg Russotti , CTO Luis Borges, CSO Michael Diem, CBO PROVEN LEADERSHIP TEAM
Slide 6: Foundational Investments in iPSC Know-How and Manufacturing
6 6 FOUNDATIONAL INVESTMENTS IN iPSC KNOW - HOW AND MANUFACTURING 6 In - House Manufacturing accelerates learnings and enables faster product iteration • Century facility expected to be operational by early 2022 • 53,000 ft 2 facility • Designed to produce multiple immune cell types • Two sites prov
Slide 7: iPSC Technology Can Overcome Limitations of Donor Derived Platforms
7 7 Allogeneic, donor - derived Multiple donors Fewer doses per batch • Complex manufacturing, heterogeneous product, limited scale • Limited genetic engineering options Allogeneic, i PSC - derived Greater doses per batch • Efficient manufacturing, homogeneous product, greater scale • Likely unlimit
Slide 8: Century's CRISPR-Mediated iPSC Gene Editing
8 8 CENTURY’S CRISPR - MEDIATED iPSC GENE EDITING 8 Highly uniform product candidates derived from fully characterized single - cell clones Proprietary CRISPR - MAD7 mediated homology directed repair (HDR) • MAD7 licensed from Inscripta . Methodology developed at Century • HDR technology enables pre
Slide 9: Overcoming Alloreactivity Challenges
9 9 OVERCOMING ALLOREACTIVITY CHALLENGES Current limitations Graft versus Host Disease Century’s solution CAR - iNK with Allo - evasion TM CAR - iT with Trusted TCR, A llo - evasion TM Prevention of Graft versus Host Disease • GvHD is circumvented with Trusted TCR Prevention of Allo - Rejection • Al
Slide 10: Allo-Evasion 1.0 Designed to Overcome Major Pathways of Host vs Graft
10 10 ALLO - EVASION TM 1.0 DESIGNED TO OVERCOME 3 MAJOR PATHWAYS OF HOST VS GRAFT b 2M KO (HLA - I) HLA - E KI CIITA KO (HLA - II) CD8 + T Cell CD4 + T Cell NK cell Deletion of β 2M, a protein required to express HLA - 1 on the cell surface prevents recognition by CD8 T cells Knock out of CIITA eli
Slide 11: Illustrative Potential of Allo-Evasion on Cellular Pharmacokinetics and Repeat Dosing
11 11 ILLUSTRATIVE POTENTIAL OF ALLO - EVASION TM ON CELLULAR PHARMACOKINETICS AND REPEAT DOSING Repeat doses With Allo - Evasion TM engineering Without Allo - Evasion TM engineering Time Cell count Initial dose Minimum threshold to maintain pharmacological pressure EK0
Slide 12: CNTY-101: CAR-iNK Candidate in R/R B-Cell Lymphoma
12 12 CNTY - 101: CAR - i NK CANDIDATE IN R/R B - CELL LYMPHOMA CNTY - 101 may change the lymphoma treatment paradigm • Has potential to use with milder lymphodepletion regimens • Potential to re - dose to enhance efficacy • Designed as an off - the - shelf cell therapy IND filing on track for mid -
Slide 13: iNK Cell Platform Is Our Most Advanced Platform
13 13 iNK CELL PLATFORM IS OUR MOST ADVANCED PLATFORM CNTY - 101, our first product candidate is a CAR - iNK cell engineered with multiple features 0 5 10 15 20 0 2.0×10 8 4.0×10 8 6.0×10 8 8.0×10 8 1.0×10 9 1.2×10 9 Day Post-tumor Implantation A v e r a g e R a d i a n c e ( p / s / c m ² / s r ) S
Slide 14: Century iT Cell Platform: TrueT Cells with Trusted TCRs
14 14 CENTURY iT CELL PLATFORM : TrueT CELLS WITH TRUSTED TCR S Unique features of Century’s iT cell platform: • Retention of a functional TCR intended to improve iT cell differentiation and functionality • Use of Trusted ab and gd which are not expected to mediate GVHD Trusted TCR is a ab viral ant
Slide 15: gd iT Cells Is One of the T Cell Platform Options
15 15 gd iT cells is one of the T cell platform options we are exploring to generate TrueT cells CAR - i T CELL PLATFORM: gd CAR - IT CELLS TrueT Cells True CAR - iT cells kill lymphoma cells similarly to peripheral blood CAR - T cells 98.9 CAR 95.2 Differentiation of gd CAR - iT cells from T - iPSC
Slide 16: iPSC-Derived gd iT Cells Mediate Serial Killing Against Lymphoma Cells
16 16 i PSC - DERIVED gd i T CELLS MEDIATE SERIAL KILLING AGAINST LYMPHOMA CELLS 0 25 50 75 100 125 150 175 200 225 250 0 1×10 6 2×10 6 3×10 6 4×10 6 Time (hours) I n c u c y t e R C U x m 2 / w e l l CAR-iT PBMC CAR-T gd CAR - iT and PBMC CAR - T cells have similar serial killing activity over 10 r
Slide 17: Our iT Cell Platform Is Close Behind and Making Demonstrable Progress
17 17 OUR i T CELL PLATFORM IS CLOSE BEHIND AND MAKING DEMONSTRABLE PROGRESS Developing ab and gd iT platforms with Trusted TCRs that are not expected to cause GvHD 0 5 10 15 20 0 5.0×10 8 1.0×10 9 1.5×10 9 2.0×10 9 2.5×10 9 Day Post-tumor Implantation A v e r a g e R a d i a n c e ( p / s / c m ² /
Slide 18: Pipeline
18 18 Product iPSC Platform Targets Indications Ownership Expected IND Submission Discovery Preclinical Phase 1 Phase 2 Phase 3 CNTY - 101 iNK CD19 Lymphoma Mid 2022 CNTY - 103 iNK CD133 + EGFR Glioblastoma 1H 2023 CNTY - 102 iT or iNK CD19 + CD79b Lymphoma 2H 2023 CNTY - 104 iT or iNK Multi - speci
Slide 19: Catalysts
19 19 CATALYSTS Event Estimated Timing Close IPO with gross proceeds of $243M 2Q21 Solicit Pre - IND written feedback for CNTY - 101 3Q21 CNTY - 101 enters IND enabling studies and manufacturing 4Q21 cGMP manufacturing facility in Branchburg NJ expected to be operational 1Q22 In vivo POC for CNTY -
Slide 20: Century's Next Generation iPSC Technology Platform
20 20 CENTURY’S NEXT GENERATION i PSC TECHNOLOGY PLATFORM Broad product pipeline with first 1 st IND submission targeting Mid - 2022 Precision gene editing Advanced manufacturing Allo - Evasion ۲ Protein engineering iPSC - derived NK cells iPSC - derived T cells Comprehensive allogeneic iPSC - based
Slide 21: Century Therapeutics
CENTURY THERAPEUTICS:
Century Therapeutics — Investor Presentation (November 2021) on 6ix